The board of directors of Cutia Therapeutics announced that results of the Phase III clinical trials of the Group's CU-40102 (topical finasteride spray) for the treatment of androgenetic alopecia and CU-10201 (topical 4% minocycline foam) for the treatment of non-nodular moderate to severe acne vulgaris in the People's Republic of China (the "PRC") were published at the 18th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology (the " 18th CDA Annual Meeting"). Results of the registrational Phase III clinical trial of CU-40102 (topically administered with CU-40102 on the local scalp area once a day. Results of the clinical trial showed that, in terms of efficacy, improvement of the total hair count and terminal hair count in the targeted bald area of the CU-40102 group was significantly better than that of the placebo group after 24 weeks of treatment.

The difference was statistically significant (P <0.05), reached primary endpoint and key secondary endpoint, and efficacy began to show from week 12. Additionally, based on the investigator assessment score of the targeted bald area, efficacy shown in the CU-40102 group is significantly better than that shown in the placebo group after 24 weeks the treatment, and the difference was statistically significant (P<0.05). In terms of safety, enrolled patients of the CU- 40102 group showed favourable local tolerance to the administration area, and the overall incidence of adverse events in the CU-40102 Group was similar to that of the placebo group.

There were no treatment-emergent serious adverse events ("TESAEs"), or treatment-emergent adverse events ("TEAEs") leading to death. Meanwhile, a Phase I pharmacokinetic study of CU-40102 in Chinese male adult patients with androgenetic alopecIA conducted in the same period showed that after the administration of finasteride spray, systemic absorption was minimal in the group of Chinese androgenetic alopecian patients. The registrational Phase III clinical trial the company has reached primary endpoint.

Results of the registrational Phase II clinical trial of CU-10201 (topicals 4% minocycline Fo) in the PRC. Results of the registrational phase III clinical trial of CU-10 201 (topical 4% minoccline foam) in the PRC. CU-10201 is the first and only topical minocycline approved for acne vulgaris treatment globally and the first topical minocycline to have its New Drug Application (the "NDA") accepted by the National Medical Products Administration (the " NMPA") of the PRC.

The registrational Phase III clinical trial of CU-10201 in the PRC was a multi-center, randomized, double-blind, and placebo-controlled trial to evaluate the efficacy and safety of patients aged nine years old or above with moderate to severe acne vulgaris. A total of 372 patients aged nine years old or higher with moderate to severe acne vulgar is enrolled in the clinical trial. During the 12-week continuous treatment period, enrolled patients were topically administered with CU-10201 on the acne site once a day.

Results of The clinical trial showed that, in term of efficacy, improvement in the inflammatory skin lesion of the CU-10201 (topically administered with CU -10201 on the acne site Once a day. Results of the registrational clinical trial showed that, in Terms of efficacy, improvement in the inflammation skin lesion of the CU -10201 (topical finasteride product approved for androgenetic alopecium) in the PRC.